Core Viewpoint - The company reported a strong performance in the first half of 2025, with significant growth in its healthcare segment, driven by its health technology business, while maintaining stability in its financial operations [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 7.581 billion yuan, a year-on-year increase of 15.9% [1] - The net profit attributable to shareholders was 1.228 billion yuan, reflecting an 8% year-on-year growth [1] Healthcare Segment - The healthcare division generated operating revenue of 4.964 billion yuan, up 27.7% year-on-year, accounting for 65.5% of total revenue [1] - The healthcare segment's net profit was 285 million yuan, a 5.3% increase, representing 21.3% of total net profit [1] - The healthcare business is divided into three segments: - Comprehensive medical services: Revenue of 4.222 billion yuan, a 15.8% increase, but net profit decreased by 14.6% due to DRG payment reform and rising fixed costs [1] - Specialized medical services: Revenue of 130 million yuan, primarily from the newly consolidated Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital [1] - Health technology: Revenue of 646 million yuan, a remarkable 142.1% increase, with equipment management contributing 418 million yuan and a net profit of 48 million yuan, up 45.9% [1] Financial Services - The financial segment reported operating revenue of 2.851 billion yuan, a 6.9% increase, with net profit reaching 1.05 billion yuan, up 7% [1] - As of June 30, 2025, the company had net interest-earning assets of 70.605 billion yuan, with a non-performing asset ratio below 1% and a 30-day overdue rate of 0.9% [1] - The company improved its financing structure and reduced costs, achieving an average cost rate of interest-bearing liabilities of 2.84% [1] Investment Outlook - The company is projected to achieve operating revenues of 14.795 billion yuan, 15.347 billion yuan, and 16.182 billion yuan for 2025-2027, with year-on-year growth rates of 8%, 4%, and 5% respectively [1] - Net profit attributable to shareholders is expected to reach 2.095 billion yuan, 2.230 billion yuan, and 2.356 billion yuan, with growth rates of 3%, 6%, and 6% respectively [1]
环球医疗(2666.HK)：2025H1经营稳健 业绩符合预期